AJAmily Fang-Ju Jou

Amily Fang-Ju Jou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amily Fang-Ju Jou has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Bo-Zhao Yang

    Department of Chemistry, Chung Yuan Christian University, No. 200, Chung Pei Road, Chung Li, Taoyuan 320314, Taiwan, ROC

    1 shared publication
  • Kuan-Ting Chen

    Department of Chemistry, Chung Yuan Christian University, No. 200, Chung Pei Road, Chung Li District, Taoyuan City, 320314, Taiwan, ROC

    1 shared publication
  • Ssu-Chia Chen

    Department of Chemistry, Chung Yuan Christian University, No. 200, Chung Pei Road, Chung Li District, Taoyuan City, 320314, Taiwan, ROC

    1 shared publication
  • Yu-Chieh Hsu

    Department of Chemistry, Chung Yuan Christian University, No. 200, Zongbei Road, Zhongli District, Taoyuan City320314, Taiwan (ROC)

    1 shared publication
  • Zheng-Yuan Su

    Department of Bioscience Technology, Chung Yuan Christian University, Taoyuan City 320314, Taiwan

    1 shared publication

Latest Publications

  • Aptamer-Engineered Cu2O Nanocubes as a Surface-Modulated Catalytic Optical Sensor for Lung Cancer Cell Detection

    by Amily Fang-Ju Jou, Yu-Chieh Hsu

    Herein, fine and homogeneous Cu2O nanocubes are synthesized and sensitized with a hairpin-structured AS1411 aptamer for the establishment of a biosensor for lung cancer cell detection. The Apt-Cu2O nanocubes feature a recognition function in identifying a cancer-associated surface nucleolin protein. The intrinsic reduction catalytic ability is also confirmed by the use of two benchmark substrates, methylene blue (MB) and 4-nitro phenol (4-NP). The aptamer grafting on Apt-Cu2O nanocubes is able to greatly prevent nonspecific-protein binding and to show specificity toward the nucleolin protein. The specific binding resulting from nucleolin protein leads to less exposure of the active area of the Apt-Cu2O nanocubes, so the catalytic ability of Apt-Cu2O nanocubes is thus diminished. The modulated catalytic ability led to less generation of the reduced 4-AP product, and the change in absorption of 4-AP allows the quantification of the nucleolin protein with a detection limit of 0.47 nM. The as-developed biosensor is applied to the detection of nucleolin-overexpressed A549 lung cancer cells, presenting a sensitive detection limit down to 20 cells. This may be ascribed to the clustering of surface nucleolin protein in a lipid raft membrane of cancer cells, as evidenced by a notable binding of Apt-Cu2O nanocubes on the cancer cell surface. Real human serum samples spiked with cancer cells were also investigated, and a recovery rate of 87 +/- 2.4% for 20 extracted cells validates the surface-modulated Apt-Cu2O nanocubes-based catalytic optical biosensor as a promising tool for the detection of circulating tumor cells. The establishment of the Apt-Cu2O nanocubes may allow for further studies on their use as a potential theranostics tool for cancer therapy.


  • Exploiting the Catalytic Ability of Polydopamine-Remodeling Gold Nanoparticles toward the Naked-Eye Detection of Cancer Cells at a Single-Cell Level

    by Bo-Zhao Yang, Zheng-Yuan Su, Amily Fang-Ju Jou

    In this study, a catalytic polydopamine-remodeling gold nanoparticle sensitized with an antinucleolin AS1411 probe (pAu nanoprobe) is synthesized, where the surface of the gold nanoparticles (AuNPs) is modified with a spontaneous self-polymerization of a polydopamine coating that imparts the probe functionalization ability and antispecific protein binding while the intrinsic catalytic property of the AuNPs is preserved. The functionalized AS1411 probe exerts specific recognition with nucleolin protein that is found to be overexpressed on the surface of breast cancer cells (MDA-MB-231). Scanning electron microscopy (SEM) confirms that the specific binding of the pAu nanoprobe occurs at the cancer cell surface. Taking advantage of the catalytic ability of the pAu nanoprobe in reducing blue-colored methylene blue (MB) to colorless leuco-MB, a colorimetric biosensing platform is established based on the accessible catalytic active sites on the pAu nanoprobe toward MB. The specific binding inhibits the pAu nanoprobe from efficiently catalyzing the reduction of MB, resulting in a “turn-off” catalytic biosensing platform. The catalytic conversion of MB is inversely proportional to the concentration of the nucleolin protein and the cancer cells, yielding a detection limit of 15 pM of the nucleolin protein and two cancer cells. The presence of five orders of magnitude higher concentration of bovine serum albumin hardly affects the catalytic ability of the pAu nanoprobe, that is, 88% catalytic ability is still preserved, which validates the specificity of the proposed pAu nanoprobe. In particular, a distinct color contrast creates a significant signal-to-noise ratio so as to enable single-cell level detection of two cancer cells by naked-eye judgment. Moreover, the undiluted, real human serum samples spiked with the cancer cells were examined with an impressive recovery of 94 ± 0.3%, which holds great promise in cancer cell screening.